A Look at the Key Issues Driving Growth in the Asian Cardiovascular Market.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31685) has announced the addition of The Asian Cardiovascular cardiovascular /car·dio·vas·cu·lar/ (-vas´ku-ler) pertaining to the heart and blood vessels. car·di·o·vas·cu·lar adj. Abbr. Market Outlook to 2010 to their offering. The Asian Cardiovascular Market Outlook to 2010 is a new management report which provides comprehensive coverage of the major cardiovascular markets in the Asia Pacific region. This report provides detailed analysis of, market trends, epidemiology epidemiology, field of medicine concerned with the study of epidemics, outbreaks of disease that affect large numbers of people. Epidemiologists, using sophisticated statistical analyses, field investigations, and complex laboratory techniques, investigate the cause , current leading brands of treatment, product sales forecast Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. and future market leaders over the period 2005-2010 in nine markets: China, India, Singapore, South Korea, Thailand, Philippines, Malaysia, Indonesia and Taiwan. The Asia Pacific region is an important market for cardiovascular products; it is estimated to have high prevalence rates for cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and associated risk factors. However, due to the increasing presence of effective generic medicine and the limited launches of innovative, the threat of underperformance facing major pharmaceutical companies is now very real. Through analysis and forecasts, this report will allow you to identify the cardiovascular market trends in developed and emerging Asian countries Noun 1. Asian country - any one of the nations occupying the Asian continent Asian nation country, land, state - the territory occupied by a nation; "he returned to the land of his birth"; "he visited several European countries" , assess the dominant forces driving market growth and develop potential growth and diversification Diversification A risk management technique that mixes a wide variety of investments within a portfolio. It is designed to minimize the impact of any one security on overall portfolio performance. Notes: Diversification is possibly the greatest way to reduce the risk. opportunities in this region over the period 2005-2010. Geographic coverage... - China - India - Indonesia - Malaysia - Singapore - South Korea -Taiwan - Thailand - The Philippines Risk factors covered - Hypertension hypertension or high blood pressure, elevated blood pressure resulting from an increase in the amount of blood pumped by the heart or from increased resistance to the flow of blood through the small arterial blood vessels (arterioles). - Dyslipidemia dyslipidemia /dys·lip·id·e·mia/ (-lip?id-e´me-ah) abnormality in, or abnormal amounts of, lipids and lipoproteins in the blood. dys·lip·i·de·mi·a n. - Diabetes Must have' statistics and analysis in this report This report provides: --Epidemiological analysis and forecast prevalence of the major cardiovascular indications and their sub-indications over the period 2005-10 in the Asia Pacific region. --Historical analysis of the performance of leading products in the four therapy areas under study. --Company analysis and market share of the top eight players in the cardiovascular area: Pfizer, Sanofi-Aventis, AstraZeneca, Merck, Novartis, Bayer, Roche and GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) . --Detailed analysis of forecast potential products in the cardiovascular area of the Asia Pacific region. --Head to head performance analysis of leading pharmaceutical corporations and company forecasts to 2010. Your questions answered --What will be the major growth indications in the cardiovascular market over the period 2005-10 in the Asia Pacific region? --In the Asia Pacific markets, which companies were the winners and losers in the cardiovascular area in 2004? --How have recent major launches from Pfizer, Sanofi-Aventis, AstraZeneca and Merck performed in the Asia Pacific region? --In the Asia Pacific region, which companies will become the key players in the cardiovascular area over the period 2005-10? --Which products will be impacted by generic competition over the period 2005-10 in the Asia Pacific market? --Which pipeline products, in the Asia Pacific region, will be the growth drivers of the future and why? --Which indications in the Asia Pacific market are forecast to have the highest levels of market potential over the period 2005-10? --What will the competitive landscape in hypertension, thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. and dyslipidemia look like in 2010? Actionable Giving sufficient legal grounds for a lawsuit; giving rise to a Cause of Action. An act, event, or occurrence is said to be actionable when there are legal grounds for basing a lawsuit on it. strategies to drive your profits forward --Save time and money in research with the report's insightful qualitative and quantitative coverage of: the major cardiovascular indications; the Asia Pacific pharmaceutical markets; and, the eight largest companies currently active in the cardiovascular market. --Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cardiovascular marketplace. --Gain up-to-date competitive intelligence across the cardiovascular portfolio and understand the major issues affecting key pharmaceutical marketers and product development. --Understand which cardiovascular indications have the greatest potential to catalyze cat·a·lyze v. To modify, especially to increase, the rate of a chemical reaction by catalysis. catalyze to cause or produce catalysis. franchise growth, and how the pharmaceutical industry is attempting to effectively utilize these opportunities. --Compare the franchises of top pharmaceutical marketers across the major indications, and understand how market share of leading companies will change over the next 5 years. Topics Covered Executive Summary Chapter 1 Patient potential Chapter 2 Regional healthcare and licensing trends Chapter 3 Regional market analysis Cardiac therapies sales forecasts Chapter 4 Key players in the Asian cardiovascular market Chapter 5 Appendix List of Figures List of Tables Companies Mentioned - Pfizer - Sanofi-Aventis - Merck & Co - AstraZeneca - Novartis - Bayer - GSK - Roche For more information visit http://www.researchandmarkets.com/reports/c31685 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion